Candel Therapeutics (CADL) News Today $6.47 +0.28 (+4.52%) Closing price 04:00 PM EasternExtended Trading$6.46 -0.01 (-0.15%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Candel Therapeutics Has A Protracted, But Real, Timeline To Approval NowOctober 13 at 12:36 PM | seekingalpha.comWeiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL)October 9, 2025 | marketbeat.comCandel Therapeutics to Present at the SITC 2025 Annual MeetingOctober 3, 2025 | globenewswire.comTanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADLOctober 2, 2025 | marketbeat.comHC Wainwright Reiterates "Buy" Rating for Candel Therapeutics (NASDAQ:CADL)September 29, 2025 | marketbeat.comCandel Therapeutics Reports Positive Phase 3 Trial Results for CAN-2409 in Intermediate-to-High-Risk Localized Prostate Cancer at ASTRO 2025September 29, 2025 | quiverquant.comQCandel trial shows promise for gene therapy in prostate cancerSeptember 29, 2025 | proactiveinvestors.comCandel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025September 29, 2025 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Buy" by AnalystsSeptember 24, 2025 | marketbeat.comCandel Therapeutics, Inc. $CADL Stock Holdings Boosted by Halter Ferguson Financial Inc.September 21, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Rating Increased to Hold at Wall Street ZenSeptember 20, 2025 | marketbeat.comCandel Therapeutics, Inc. Announces Oral Presentation of CAN-2409 Data at 2025 ASTRO Annual MeetingSeptember 17, 2025 | quiverquant.comQCandel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025September 17, 2025 | globenewswire.comCandel Therapeutics, Inc. $CADL Shares Bought by Acorn Capital Advisors LLCSeptember 11, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Downgraded by Wall Street Zen to SellSeptember 8, 2025 | marketbeat.comCandel Therapeutics: Potentially The Next Exciting Oncology StorySeptember 7, 2025 | seekingalpha.comNuveen LLC Buys Shares of 78,145 Candel Therapeutics, Inc. $CADLSeptember 7, 2025 | marketbeat.comCandel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough TumorsSeptember 5, 2025 | seekingalpha.comCandel Therapeutics (NASDAQ:CADL) Rating Lowered to "Neutral" at Bank of AmericaSeptember 5, 2025 | marketbeat.comBaker BROS. Advisors LP Sells 544,794 Shares of Candel Therapeutics, Inc. $CADLSeptember 4, 2025 | marketbeat.comB of A Securities Downgrades Candel Therapeutics (CADL)September 4, 2025 | msn.comErasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalystsSeptember 3, 2025 | msn.comCandel Therapeutics downgraded to Neutral at BofA on lack of catalystsSeptember 3, 2025 | msn.comCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory BoardSeptember 2, 2025 | ca.finance.yahoo.comCandel Therapeutics adds immunotherapy expert to Research Advisory BoardSeptember 2, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.September 2, 2025 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Consensus Rating of "Buy" from BrokeragesSeptember 1, 2025 | marketbeat.comCandel Therapeutics, Inc. Announces Participation in Upcoming Investor ConferencesAugust 28, 2025 | quiverquant.comQCandel Therapeutics to Participate in Upcoming Investor Conferences in SeptemberAugust 28, 2025 | globenewswire.comCandel Therapeutics Extends Lease Agreement in NeedhamAugust 22, 2025 | msn.comCandel Therapeutics Advances with Promising Cancer TherapiesAugust 18, 2025 | tipranks.comCandel Therapeutics (NASDAQ:CADL) Posts Earnings Results, Beats Expectations By $0.08 EPSAugust 16, 2025 | marketbeat.comCandel Therapeutics secures RMAT for prostate cancer – ICYMIAugust 16, 2025 | proactiveinvestors.comCandel Therapeutics secures RMAT for prostate cancer – ICYMIAugust 16, 2025 | proactiveinvestors.comCandel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer TreatmentAugust 16, 2025 | msn.comCandel Therapeutics reports Q2 EPS (9c) vs. (74c) last yearAugust 14, 2025 | msn.comCandel Therapeutics files $300M mixed securities shelfAugust 14, 2025 | msn.comCandel Therapeutics advances toward prostate cancer therapy filing after trial successAugust 14, 2025 | proactiveinvestors.comCandel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 14, 2025 | globenewswire.comWith 44% stake, Candel Therapeutics, Inc. (NASDAQ:CADL) seems to have captured institutional investors' interestAugust 8, 2025 | finance.yahoo.comCandel Therapeutics (CADL) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Rating of "Buy" from BrokeragesAugust 5, 2025 | marketbeat.comCandel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comCandel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409July 24, 2025 | proactiveinvestors.comCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic CancerJuly 24, 2025 | globenewswire.comResearch Analysts Offer Predictions for CADL Q2 EarningsJuly 14, 2025 | marketbeat.comCandel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value ...July 11, 2025 | nasdaq.comCandel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Upgraded to "Strong-Buy" at Brookline Capital ManagementJuly 11, 2025 | marketbeat.comCandel Therapeutics expands Russell Index presence following 2025 reconstitutionJuly 9, 2025 | proactiveinvestors.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼0.860.76▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼44▲CADL Articles Average Week Get the Latest News and Ratings for CADL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Candel Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TRVI News Today AMLX News Today MAZE News Today ELVN News Today PRAX News Today IMTX News Today WVE News Today DNTH News Today ORIC News Today PHAR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
